Jose Monzon, B.Sc., Ling Liu, M.D., Herbert Brill, B.Sc., Alisa M. Goldstein, Ph.D., Margaret A. Tucker, M.D., Lynn From, M.D., John McLaughlin, Ph.D., David Hogg, M.D., and Norman J. Lassam, M.D., Ph.D.
Background Germ-line mutations in the CDKN2A tumor-suppressorgene (also known as p16, p16INK4a, and MTS1) have been linkedto the development of melanoma in some families with inheritedmelanoma. Whether mutations in CDKN2A confer a predispositionto sporadic (nonfamilial) melanoma is not known. In some patientswith sporadic melanoma, one or more additional primary lesionsdevelop, suggesting that some of these patients have an underlyinggenetic susceptibility to the cancer. We hypothesized that thispredisposition might be due to germ-line CDKN2A mutations.
Methods We used the polymerase chain reaction, single-strandconformation polymorphism analysis, and direct DNA sequencingto identify germ-line mutations in the CDKN2A gene in patientswith multiple primary melanomas who did not have family historiesof the disease. A quantitative yeast two-hybrid assay was usedto evaluate the functional importance of the CDKN2A variants.
Results Of 33 patients with multiple primary melanomas, 5 (15percent; 95 percent confidence interval, 4 percent to 27 percent)had germ-line CDKN2A mutations. These included a 24-bp insertionat the 5' end of the coding sequence, three missense mutations(Arg24Pro, Met53Ile, and Ser56Ile), and a 2-bp deletion at position307 to 308 (resulting in a truncated CDKN2A protein). In threefamilies, CDKN2A mutations identical to those in the probandswere found in other family members. In two families with mutations,we uncovered previously unknown evidence of family historiesof melanoma.
Conclusions Some patients with multiple primary melanomas butwithout family histories of the disease have germ-line mutationsof the CDKN2A gene. The presence of multiple primary melanomasmay signal a genetic susceptibility to melanoma not only inthe index patient but also in family members, who may benefitfrom melanoma-surveillance programs.
Source Information
From the Institute of Medical Sciences (J. Monzon, D.H., N.J.L.), the Department of Medical Biophysics (L.L., H.B., D.H., N.J.L.), and the Departments of Dermatology (L.F.) and Preventive Medicine and Biostatistics (J. McLaughlin), University of Toronto, Toronto; the Genetic Epidemiology Branch, National Cancer Institute, Bethesda, Md. (A.M.G., M.A.T.); and the Division of Medical Oncology, TorontoSunnybrook Regional Cancer Centre, Toronto (N.J.L.).
Address reprint requests to Dr. Lassam at TorontoSunnybrook Regional Cancer Centre, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada.
Dorshorst, B. J., Ashwell, C. M.
(2009). Genetic mapping of the sex-linked barring gene in the chicken. Poult. Sci.
88: 1811-1817
[Abstract][Full Text]
Eliason, M. J., Hansen, C. B., Hart, M., Porter-Gill, P., Chen, W., Sturm, R. A., Bowen, G., Florell, S. R., Harris, R. M., Cannon-Albright, L. A., Swinyer, L., Leachman, S. A.
(2007). Multiple Primary Melanomas in a CDKN2A Mutation Carrier Exposed to Ionizing Radiation. Arch Dermatol
143: 1409-1412
[Abstract][Full Text]
Jones, R., Ruas, M., Gregory, F., Moulin, S., Delia, D., Manoukian, S., Rowe, J., Brookes, S., Peters, G.
(2007). A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6. Cancer Res.
67: 9134-9141
[Abstract][Full Text]
Goldstein, A. M, Chan, M., Harland, M., Hayward, N. K, Demenais, F., Timothy Bishop, D, Azizi, E., Bergman, W., Bianchi-Scarra, G., Bruno, W., Calista, D., Cannon Albright, L. A, Chaudru, V., Chompret, A., Cuellar, F., Elder, D. E, Ghiorzo, P., Gillanders, E. M, Gruis, N. A, Hansson, J., Hogg, D., Holland, E. A, Kanetsky, P. A, Kefford, R. F, Teresa Landi, M., Lang, J., Leachman, S. A, MacKie, R. M, Magnusson, V., Mann, G. J, Newton Bishop, J., Palmer, J. M, Puig, S., Puig-Butille, J. A, Stark, M., Tsao, H., Tucker, M. A, Whitaker, L., Yakobson, E., The Lund Melanoma Study Group, , and the Melanoma Genetics Consortium (GenoMEL),
(2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet.
44: 99-106
[Abstract][Full Text]
Niendorf, K B, Goggins, W, Yang, G, Tsai, K Y, Shennan, M, Bell, D W, Sober, A J, Hogg, D, Tsao, H
(2006). MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J. Med. Genet.
43: 501-506
[Abstract][Full Text]
Debniak, T, Gorski, B, Huzarski, T, Byrski, T, Cybulski, C, Mackiewicz, A, Gozdecka-Grodecka, S, Gronwald, J, Kowalska, E, Haus, O, Grzybowska, E, Stawicka, M, Swiec, M, Urbanski, K, Niepsuj, S, Wasko, B, Gozdz, S, Wandzel, P, Szczylik, C, Surdyka, D, Rozmiarek, A, Zambrano, O, Posmyk, M, Narod, S A, Lubinski, J
(2005). A common variant of CDKN2A (p16) predisposes to breast cancer. J. Med. Genet.
42: 763-765
[Abstract][Full Text]
Puig, S., Malvehy, J., Badenas, C., Ruiz, A., Jimenez, D., Cuellar, F., Azon, A., Gonzalez, U., Castel, T., Campoy, A., Herrero, J., Marti, R., Brunet-Vidal, J., Mila, M.
(2005). Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas. JCO
23: 3043-3051
[Abstract][Full Text]
Loercher, A. E., Tank, E. M.H., Delston, R. B., Harbour, J. W.
(2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. JCB
168: 35-40
[Abstract][Full Text]
Landi, M T, Goldstein, A M, Tsang, S, Munroe, D, Modi, W, Ter-Minassian, M, Steighner, R, Dean, M, Metheny, N, Staats, B, Agatep, R, Hogg, D, Calista, D
(2004). Genetic susceptibility in familial melanoma from northeastern Italy. J. Med. Genet.
41: 557-566
[Full Text]
Tsao, H., Sober, A. J., Niendorf, K. B., Zembowicz, A.
(2004). Case 7-2004 - A 48-Year-Old Woman with Multiple Pigmented Lesions and a Personal and Family History of Melanoma. NEJM
350: 924-932
[Full Text]
Hampel, H, Sweet, K, Westman, J A, Offit, K, Eng, C
(2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet.
41: 81-91
[Abstract][Full Text]
Laud, K., Kannengiesser, C., Avril, M.-F., Chompret, A., Stoppa-Lyonnet, D., Desjardins, L., Eychene, A., Demenais, F., French Hereditary Melanoma Study Group, , Lenoir, G. M., Bressac-de Paillerets, B.
(2003). BRAF as a Melanoma Susceptibility Candidate Gene?. Cancer Res.
63: 3061-3065
[Abstract][Full Text]
Koenig, A., Bianco, S. R., Fosmire, S., Wojcieszyn, J., Modiano, J. F.
(2002). Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma. Vet Pathol
39: 458-472
[Abstract][Full Text]
Orlow, I., Roy, P., Barz, A., Canchola, R., Song, Y., Berwick, M.
(2001). Validation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for the Identification of Human INK4A Gene Mutations. J. Mol. Diagn.
3: 158-163
[Abstract][Full Text]
Goldstein, A. M., Tucker, M. A.
(2001). Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective. Arch Dermatol
137: 1493-1496
[Full Text]
Becker, T. M., Rizos, H., Kefford, R. F., Mann, G. J.
(2001). Functional Impairment of Melanoma-associated p16INK4a Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding. Clin. Cancer Res.
7: 3282-3288
[Abstract][Full Text]
van der Velden, P. A., Metzelaar-Blok, J. A. W., Bergman, W., Monique, H., Hurks, H., Frants, R. R., Gruis, N. A., Jager, M. J.
(2001). Promoter Hypermethylation: A Common Cause of Reduced p16INK4a Expression in Uveal Melanoma. Cancer Res.
61: 5303-5306
[Abstract][Full Text]
Schraml, P., Struckmann, K., Bednar, R., Fu, W., Gasser, T., Wilber, K., Kononen, J., Sauter, G., Mihatsch, M. J., Moch, H.
(2001). CDKN2A Mutation Analysis, Protein Expression, and Deletion Mapping of Chromosome 9p in Conventional Clear-Cell Renal Carcinomas : Evidence for a Second Tumor Suppressor Gene Proximal to CDKN2A. Am. J. Pathol.
158: 593-601
[Abstract][Full Text]
Hashemi, J., Platz, A., Ueno, T., Stierner, U., Ringborg, U., Hansson, J.
(2000). CDKN2A Germ-line Mutations in Individuals with Multiple Cutaneous Melanomas. Cancer Res.
60: 6864-6867
[Abstract][Full Text]
Nishiwaki, E., Turner, S. L., Harju, S., Miyazaki, S., Kashiwagi, M., Koh, J., Serizawa, H.
(2000). Regulation of CDK7-Carboxyl-Terminal Domain Kinase Activity by the Tumor Suppressor p16INK4A Contributes to Cell Cycle Regulation. Mol. Cell. Biol.
20: 7726-7734
[Abstract][Full Text]
Çelebi, J. T., Shendrik, I., Silvers, D. N, Peacocke, M.
(2000). Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet.
37: 653-657
[Abstract][Full Text]
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., Haluska, F. G.
(2000). Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma. Arch Dermatol
136: 1118-1122
[Abstract][Full Text]
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., Ingvar, C.
(2000). High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families. JNCI J Natl Cancer Inst
92: 1260-1266
[Abstract][Full Text]
Brantley, M. A. Jr., Harbour, J. W.
(2000). Inactivation of Retinoblastoma Protein in Uveal Melanoma by Phosphorylation of Sites in the COOH-Terminal Region. Cancer Res.
60: 4320-4323
[Abstract][Full Text]
PORTWINE, C., LEES, J., VERSELIS, S., LI, F. P, MALKIN, D.
(2000). Absence of germline p16INK4a alterations in p53 wild type Li-Fraumeni syndrome families. J. Med. Genet.
37: 13e-13
[Full Text]
Lal, G., Liu, G., Schmocker, B., Kaurah, P., Ozcelik, H., Narod, S. A., Redston, M., Gallinger, S.
(2000). Inherited Predisposition to Pancreatic Adenocarcinoma: Role of Family History and Germ-Line p16, BRCA1, and BRCA2 Mutations. Cancer Res.
60: 409-416
[Abstract][Full Text]
Kefford, R. F., Newton Bishop, J. A., Bergman, W., Tucker, M. A.
(1999). Counseling and DNA Testing for Individuals Perceived to Be Genetically Predisposed to Melanoma: A Consensus Statement of the Melanoma Genetics Consortium. JCO
17: 3245-3251
[Full Text]
Ruiz, A., Puig, S., Malvehy, J., Lázaro, C., Lynch, M., Gimenez-Arnau, A. M, Puig, L., Sánchez-Conejo, J., Estivill, X., Castel, T.
(1999). CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J. Med. Genet.
36: 490-493
[Abstract][Full Text]
Gilchrest, B. A., Eller, M. S., Geller, A. C., Yaar, M.
(1999). The Pathogenesis of Melanoma Induced by Ultraviolet Radiation. NEJM
340: 1341-1348
[Full Text]
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., Hayward, N.
(1999). CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma. JNCI J Natl Cancer Inst
91: 446-452
[Abstract][Full Text]
Burden, A. D., Newell, J., Andrew, N., Kavanagh, G., Connor, J. M., MacKie, R. M.
(1999). Genetic and Environmental Influences in the Development of Multiple Primary Melanoma. Arch Dermatol
135: 261-265
[Abstract][Full Text]
Grob, J.-J.
(1999). Multiple Primary Melanoma Is Not a Distinct Biological Entity. Arch Dermatol
135: 325-327
[Full Text]
Bystryn, J.-C., Hughes-Davies, T.H., Lassam, N. J., Hogg, D., McLaughlin, J.
(1998). CDKN2A Mutations in Multiple Primary Melanomas. NEJM
339: 347-348
[Full Text]
Clurman, B. E., Groudine, M.
(1998). The CDKN2A Tumor-Suppressor Locus -- A Tale of Two Proteins. NEJM
338: 910-912
[Full Text]
Rizos, H., Darmanian, A. P., Holland, E. A., Mann, G. J., Kefford, R. F.
(2001). Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF. J. Biol. Chem.
276: 41424-41434
[Abstract][Full Text]